Showing 1 - 10 of 136
This paper models payment evasion as a source of profit by letting the firm choose the purchase price and the fine imposed on detected payment evaders. For a given price and fine, the consumers purchase, evade payment, or choose the outside option. We show that payment evasion leads to a form of...
Persistent link: https://www.econbiz.de/10011276378
led to patterns of behaviour that suggest imperfect competition and market segmentation. At times in the past, the …
Persistent link: https://www.econbiz.de/10005136669
An uninformed seller offers an object to a privately informed buyer. The buyer projects information and exaggerates the probability that the seller is informed. Letting the buyer bargain and name her own price raises the seller's payoff above the full-commitment payoff. Under seller-offer...
Persistent link: https://www.econbiz.de/10011168901
Pricing policy for any experience good faces a key tradeoff. On one hand, a price reduction increases immediate demand …
Persistent link: https://www.econbiz.de/10011083717
In this paper, we examine how cross-market price restrictions impact strategic entry and pricing decisions. A … motivating example is the 1996 Act in the United States which opens telecommunications markets to competition and contains a …
Persistent link: https://www.econbiz.de/10005792026
innovation policy in the context of EU economic law (competition policy, intellectual property law, sector regulation). As such … pharmaceuticals, specifically drug reformulation regulatory gaming. …
Persistent link: https://www.econbiz.de/10009205060
This paper addresses the relationship between patent protection and investment in the development of new pharmaceutical treatments. The TRIPS Agreement, which specifies minimum levels of intellectual property protection for countries in the World Trade Organization, has increased levels of...
Persistent link: https://www.econbiz.de/10009002387
the hypothesis that innovation in pharmaceuticals is becoming more difficult and expensive over time, as costs of …
Persistent link: https://www.econbiz.de/10009003149
creating an internal market for pharmaceuticals can be analysed. In a model of third-degree price discrimination, arbitrage … Market in pharmaceuticals are ambiguous, since a movement from segmented and price-controlled markets towards integrated …
Persistent link: https://www.econbiz.de/10005114350
Preventives are sold ex ante, before disease status is realized, while treatments are sold ex post. Even if the mean of the ex ante distribution of consumer values is the same as that ex post, the shape of the distributions may differ, generating a difference between the surplus each product can...
Persistent link: https://www.econbiz.de/10011196028